I
n sickle cell disease (SCD), a group of inherited disorders of haemoglobin where pathology is caused by sickle (HbS) haemoglobin, the major pathophysiological basis of the morbidity and mortality is microvascular vaso-occlusion. Vaso-occlusion in the microcirculation of the peripheral retina in SCD results in ischaemia, a response to which is a sequence of pathological vascular events leading to proliferative sickle retinopathy (PSR), eventually causing visual loss in 10-12% of eyes. 1 2 However, the determinants of PSR progression or autoinfarction are unknown. 3 Vascular endothelial growth factor (VEGF), a potent, secreted growth factor that promotes angiogenesis, is a possible stimulus for retinal proliferation, as its expression is upregulated by hypoxia. 4 High intraocular VEGF is found in patients with active intraocular neovascularisation, 5 6 supporting the view of a role in vasoproliferation/neovascularisation.
Changes in both plasma and intraocular VEGF levels have been related to laser treatment. 5 7 VEGF interacts with endothelial cells via membrane spanning receptors Flt-1 and KDR and the role of Flt-1 in embryonic vasculogenesis and adult angiogenesis and its association with several diseases has been clearly established. 8 Angiopoietin-1 and angiopoietin-2 (Ang-1, Ang-2), members of another family of vascular growth factors, interact with the endothelial cell specific tyrosine kinase receptor Tie-2. 9 Ang-1 acts via the Tie-2 receptor to remodel primitive vessels and help maintain and stabilise the mature vessels by promoting interaction between endothelial cells and surrounding support cells. 10 11 Ang-2, conversely, leads to destabilisation of vessels and dissociation of pericytes, and is upregulated by hypoxia and angiogenic cytokines, including VEGF 12 13 and in pathological angiogenesis associated with tumours 10 11 and choroidal neovasculariation associated with age related macular degeneration. 14 Thus, the precise balance of VEGF and the angiopoetin/Tie-2 system is essential for modulating growing vessels and maintaining the integrity of existing vessels, thereby determining whether vessels proliferate and become leaky.
Abnormally raised levels of VEGF have been reported in SCD 15 but any role in associated eye disease is unclear. We therefore hypothesised abnormal Ang-1, Ang-2, sFlt-1, and sTie-2 in SCD, measuring VEGF as an effective positive control and vWf as an index of endothelial damage/ dysfunction. We further hypothesised a graded increase in these markers in SCD patients with no retinopathy (NR), others with non-proliferative retinopathy (NPR), and others with proliferative sickle retinopathy (PSR). To test these hypotheses, we undertook a cross sectional study. Finally, we hypothesised that these indices fall after treatment with panretinal laser photocoagulation (PRP), and conducted a longitudinal study, measuring our research indices before and 6 months after laser treatment.
PATIENTS AND METHODS
Patients with SCD who attended the Sickle Cell and Thalassemia (SCAT) Centre were recruited. Diagnosis (HbSS or HbSC) was proved using routine high performance liquid chromatography (HPLC). Patients were excluded if they had previously received laser treatment for proliferative retinopathy or had eye surgery, were receiving regular red cell exchange tranfusion, had blood tranfusion within the previous 3 months, had any malignancy, connective tissue disease or vascular disease, diabetes, hypertension, were pregnant, or were on long term medication (such as hydroxyurea). None of the patients had a painful crisis within 2 weeks of the time of ocular examinations and blood sampling. The healthy control group of subjects with normal haemoglobin genotype (AA subjects) were matched for age, sex, and ethnic origin with the PSR patients.
The diagnoses of PSR, NPR, or no retinopathy (NR) were made using slit lamp biomicroscopy and fluorescein angiography. 5 The characteristic confirming feature of the diagnosis of peripheral retinal neovascularisation was intense hyperfluorescence caused by leakage of dye from new blood vessels. Patients with PSR who showed evidence of leakage on fluorescein angiogram (''leaky PSR'') were offered laser treatment with sectoral panretinal photocoagulation (PRP).
A volume of 10 ml of citrated venous blood was obtained for measurement of plasma Ang-1, Ang-2, Tie-2, VEGF, sFlt-1, and vWf. For patients with NR or with NPR, this was the only occasion on which a blood sample was taken. In patients with ''leaky PSR'' a blood sample was repeated at 5-7 (median 6) months after their last laser treatment. Blood samples were taken from the antecubital vein with minimal stasis into Vacuette tubes containing 3.2% sodium citrate and centrifuged at 3000 rpm at 4˚C for 20 minutes. The platelet free plasma was immediately separated and frozen at 270˚C. Research indices were measured by ELISA using commercially available reagents and recombinant standards (R&D Systems, Abingdon, UK).
Data are presented as mean (SD) or median (interquartile range (IQR)) and compared by the unpaired t test and by the Mann-Whitney U test, or the one way ANOVA and Table 1 Plasma levels of angiopoietin-1 (Ang-1) angiopoietin-2 (Ang-2), the soluble angiopoietin receptor Tie-2 (Tie-2), vascular endothelial growth factor (VEGF), its soluble receptor Flt-1, and von Willebrand factor (vWf) in patients with sickle cell disease (SCD) and subjects with normal haemoglobin (AA) The study cohort of 56 SCD (26 men, mean (SD) age 33.5 (10) Kruskall-Wallis test as appropriate. Correlations were performed using Spearman's rank correlation test. Paired comparisons were tested using the paired Wilcoxon test.
RESULTS
Plasma levels of Ang-1, Tie-2, VEGF, sFlt-1, and vWf did not differ between the groups, although Ang-2 was higher in the SS patients (p = 0.025); therefore, data were pooled for further analysis. Plasma levels of Ang-1 and Ang-2 (but not Tie-2 or sFlt-1) were significantly raised in the SCD patients compared to levels in the AA subjects (table 1) . As expected, 15 16 VEGF and vWf were higher in SCD. The ratios of Ang-2 to VEGF, Ang-1 to VEGF, and between all three growth factors (that is [Ang-1/Ang-26100]/VEGF) were lower in the SCD patients than in the controls but there was no statistical difference in the Ang-2/Ang-1 ratio. There were no differences in Ang-1, Ang-2, Tie-2, VEGF, sFlt-1, and vWf levels among the patients (table 2). The ratio [(Ang-1/ Ang-2)6100]/VEGF was higher in NR than in the two other groups.
In the AA subjects, the most significant correlations were between Ang-1 and VEGF, Ang-1 and Tie-2, and VEGF and sFlt-1 (table 3) . Stronger positive correlations were also apparent between the same molecules in the patients with SCD (table 3) . Furthermore, in SCD, Ang-2 was highly correlated with Ang-1, Tie-2 with VEGF, and Ang-1 weakly with vWf. Within each of the SCD subgroups, Ang-1 was significantly correlated with Ang-2, with VEGF and with Tie-2; similarly, Ang-2 was significantly correlated with VEGF and Tie-2, (except in the NPR patients) and VEGF with sFlt-1 (table 4).
Plasma Ang-2 fell but Tie-2 rose significantly in eight patients (one male, mean age 34 (SD 9)) following PRP therapy (table 5), but Ang-1, VEGF, sFlt-1, and vWf levels did not change. Ocular examination showed only partial or incomplete resolution of neovascularisation at the time of the follow up blood sample in all the patients.
DISCUSSION
The current novel findings of elevated plasma Ang-2 in SCD, alongside raised VEGF, are consistent with the concept of increased angiogenic activity in SCD generally. The observations of elevated plasma VEGF 15 (up to ,10-fold) and vWf 16 confirm previous reports. The precise cause for the increased angiogenesis is unclear, but increased systemic tissue hypoxia consequent to generalised subclinical vaso-occlusion may contribute to the elevated plasma Ang-2 and VEGF levels. Marked endothelial damage/dysfunction is associated with SCD 16 and endothelial proliferation as a means of effecting endothelial repair may be a mechanism for attempting to preserve endothelial homeostasis. As Ang-1 has been shown to have anti-apoptotic effects on endothelial cells, 17 18 we speculate that because of the endothelial damage in SCD, Ang-1 levels are raised in order to provide this support. Our observation of a significant correlation between Ang-1 and vWf in SCD, but not in controls, lends support to this hypothesis.
Destabilisation of growing blood vessels by Ang-2, in the absence of VEGF, leads to vessel regression, whereas such destabilisation in the presence of high VEGF levels facilitates the angiogenic response. [9] [10] [11] Thus, the precise balance of VEGF and the angiopoetin/Tie-2 system is important in determining whether or not vessels auto-infarct and regress/ atrophy or proliferate and become leaky. We would therefore expect that in PSR patients, retinal vaso-occlusion leads to retinal ischaemia and hypoxia, which induces high levels of VEGF and Ang-2. Conversely, in patients without retinopathy, there might be relatively greater retinal vaso-occlusion possibly also accompanied by greater levels of auto-infarction-leading to less retinal ischaemia and less hypoxia than in PSR patients, and lower levels of VEGF and Ang-2 than in PSR patients. It follows that Ang-2, in the presence of very low levels of VEGF, might induce neovascular regression.
An ''angiogenic index,'' reflecting the ratio of Ang-2 to VEGF and/or the combined angiopoietins to VEGF might be indicators of the presence or development of PSR, with a low index (high Ang-2/high VEGF) indicating the tendency to new vessel proliferation and leakiness, and a high index (mid-high Ang2/low VEGF) indicating tendency to neovascular regression and atrophy. Our observations of lower ratios of the angiopoietins (individually or combined) in SCD compared to AA subjects as well as the trend of lower Ang-2/ VEGF from ''no retinopathy'' to PSR is consistent with this. In SCD, the strong intercorrelations among the growth factors, suggest a high degree of coordinated and complementary angiogenic activity and perhaps a role for these factors in abnormal angiogenesis in SCD; however, no clear patterns emerged according to severity of retinopathy.
The role of the angiopoietins and their interaction with VEGF (if any) in retinal neovascularisation is not fully understood. In human retinal tissue, Ang-2 and Tie-2 expression appears to be associated with ischaemic retinal disorders 19 and VEGF expression with abnormal proliferation in SCD. 20 However, the idea that angiogenic activity is further heightened in SCD patients with PSR was not supported by the present findings. The observed lack of difference in any molecule among the SCD patients may be attributable to their existing elevated levels that may obscure any further increase in their levels in different eye conditions. Table 5 The effect of laser treatment (PRP) on plasma levels of angiopoietin-1 (Ang-1) angiopoietin-2 (Ang-2), the soluble angiopoietin receptor Tie-2, VEGF, sFlt-1 and vWf in eight patients with sickle haemoglobin C disease with ''leaky PSR'' 
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